Salarius Pharmaceuticals (SLRX) Institutional Ownership $0.89 -0.01 (-0.98%) As of 07/3/2025 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Salarius Pharmaceuticals (NASDAQ:SLRX)CurrentInstitutional OwnershipPercentage11.88%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$145.78K Get SLRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Salarius Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SLRX Institutional Buying and Selling by Quarter Salarius Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2024Armistice Capital LLC22,750$54K0.0%-72.9%3.811% 2/13/2024Armistice Capital LLC88,000$57K0.0%-60.9%2.234% 11/15/2023Armistice Capital LLC225,000$148K0.0%+105.2%5.711% 11/15/2021HighTower Advisors LLC26,000$26K0.0%N/A0.058% 11/9/2021BlackRock Inc.116,309$119K0.0%-13.7%0.260% 8/25/2021Marshall Wace LLP174,474$185K0.0%+29.6%0.390% 8/17/2021X Square Capital LLC100,458$106K0.1%-39.4%0.224% 8/16/2021Maven Securities LTD1,316,205$1.37M0.1%-31.7%2.939% 8/16/2021State Street Corp142,552$151K0.0%N/A0.318% 8/16/2021Sabby Management LLC249,033$264K0.0%-6.7%0.556% 8/16/2021Marshall Wace LLP174,474$185K0.0%+29.6%0.390% 8/13/2021Northern Trust Corp65,022$69K0.0%+25.9%0.145% 8/13/2021Geode Capital Management LLC277,035$293K0.0%+124.4%0.619% 8/13/2021Vanguard Group Inc.1,544,724$1.64M0.0%+8.7%3.450% 8/12/2021Dimensional Fund Advisors LP36,634$39K0.0%-40.8%0.082% 5/19/2021Worth Venture Partners LLC424,800$629K0.3%+17.8%0.949% 5/18/2021Millennium Management LLC28,675$42K0.0%+40.5%0.064% 5/18/2021Silverarc Capital Management LLC1,992,181$2.95M1.6%N/A4.450% 5/14/2021Dimensional Fund Advisors LP61,839$92K0.0%N/A0.138% 5/13/2021Renaissance Technologies LLC237,601$352K0.0%N/A0.531% 5/12/2021Northern Trust Corp51,648$76K0.0%+248.6%0.115% 5/12/2021Geode Capital Management LLC123,461$182K0.0%+573.5%0.276% (Data available from 1/1/2016 forward) SLRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SLRX shares? During the previous two years, the following institutional investors and hedge funds held shares of Salarius Pharmaceuticals shares: Armistice Capital LLC ($54K).Learn more on Salarius Pharmaceuticals' institutional investors. What percentage of Salarius Pharmaceuticals' stock is owned by institutional investors? 11.88% of Salarius Pharmaceuticals' stock is owned by institutional investors. Learn more on SLRX's institutional investor holdings. Which institutional investors have been buying Salarius Pharmaceuticals' stock? The following institutional investors have purchased Salarius Pharmaceuticals' stock in the last 24 months: Armistice Capital LLC ($115.36K). Which of Salarius Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold Salarius Pharmaceuticals stock in the last 24 months: Armistice Capital LLC ($61.25K). How much institutional selling is happening at Salarius Pharmaceuticals? Institutional investors have sold a total of 61,250 shares in the last 24 months. This volume of shares sold represents approximately $145.78K in transactions. Related Companies TCRT Institutional Ownership SNPX Institutional Ownership TSBX Institutional Ownership BMRA Institutional Ownership TRAW Institutional Ownership CYCC Institutional Ownership CLDI Institutional Ownership APLM Institutional Ownership PMCB Institutional Ownership SLXN Institutional Ownership This page (NASDAQ:SLRX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
